☰

First Patients Treated in Cytori´s Stem & Regenerative Cell Heart Attack Study


    Cytori Therapeutics (NASDAQ:CYTX) enrolled the first two patients
    in a clinical trial using adipose-derived stem and regenerative cells
    in the treatment of heart attack. In this trial, patients´ cells are
    made available using Cytori´s Celution(TM) System, a real-time cell
    processing device. One patient has been enrolled in each trial center,
    Hospital Universitario Gregorio Maranon in Madrid, Spain, and
    Thoraxcenter, Erasmus Medical Center in Rotterdam, The Netherlands.

    Fat, known medically as adipose tissue, is one of the body´s
    richest known sources of regenerative cells. Adipose-derived
    regenerative cells include adult stem cells in addition to other
    important cell types that have been shown to increase blood flow in
    and around damaged and oxygen deprived tissues. As a result, these
    cells hold exciting potential to revolutionize the treatment of heart
    disease, which affects millions of patients worldwide each year.

    "Time is of the essence in the treatment of patients with heart
    attacks," said Prof. PW. Serruys, M.D., Ph.D., principal investigator
    for the trial and Head of the Department of Interventional Cardiology
    at the Thoraxcenter, Erasmus Medical Center. "The Celution(TM) System
    makes adipose-derived regenerative cells available in real-time and
    enables early treatment. For this reason, adipose-derived regenerative
    cells processed by the Celution(TM) System could play a critical role
    in limiting or reversing heart damage caused by a heart attack."

    "A major challenge in cardiovascular cell therapy is having a
    meaningful number of stem and regenerative cells," said Francisco J.
    Fernandez-Aviles, Chief of Department of Cardiology at Hospital
    Universitario Gregorio Maranon and an investigator for this APOLLO
    trial. "To date, we have treated a number of patients with chronic
    ischemia in Cytori´s PRECISE trial, and we are pleased that the
    Celution(TM) device has enabled us to administer a meaningful dose of
    their own cells in real-time."

    The APOLLO trial is a 48-patient, randomized, placebo-controlled,
    dose escalation, safety and feasibility multi-center study. A dose of
    adipose-derived regenerative cells, or a placebo, will be delivered
    through an intracoronary catheter within 36 hours following the onset
    of a heart attack. The trial will involve four groups of 12 patients
    each. In each group, nine patients will receive cells and three will
    receive the placebo control. Cytori is the sole sponsor of the APOLLO
    clinical trial.

    "The Celution(TM) System is unique in its ability to potentially
    address acute and chronic heart conditions using a patient´s own
    cells," said Alex Milstein, M.D., Vice President, Clinical
    Development, Cytori Therapeutics. "Cytori´s comprehensive clinical
    development program for the Celution system addresses chronic ischemic
    heart disease as well as in acute heart attack. The initiation of the
    APOLLO trial is an important milestone that has a potential of
    bringing innovative treatment options for patients with acute heart
    attack."

    Cytori Therapeutics

    Cytori Therapeutics´ (NASDAQ:CYTX) goal is to be the global leader
    in regenerative medicine. The company is dedicated to providing
    patients with new options for reconstructive surgery, developing
    treatments for cardiovascular disease, and banking patients´ adult
    stem and regenerative cells. To reach its goal, Cytori is developing
    its innovative Celution(TM) System to separate and concentrate a
    patient´s own adult stem and regenerative cells from adipose (fat)
    tissue for these cells to be delivered back to the patient during the
    same surgical procedure. In 2008, the Celution(TM) System is being
    introduced in Europe into the reconstructive surgery market and
    launched in Japan for cryopreserving a patient´s own stem and
    regenerative cells. Clinical trials are ongoing or planned in
    cardiovascular disease, spinal disc degeneration, gastrointestinal
    disorders, and other unmet medical needs. www.cytoritx.com

    Cautionary Statement Regarding Forward-Looking Statements

    This press release includes forward-looking statements regarding
    events, trends and prospects of our business, which may affect our
    future operating results and financial position. Such statements are
    subject to risks and uncertainties that could cause our actual results
    and financial position to differ materially. Some of these risks and
    uncertainties include our history of operating losses, the need for
    further financing, regulatory uncertainties, dependence on performance
    of third parties, and other risks and uncertainties described (under
    the heading "Risk Factors") in Cytori Therapeutics´ Form 10-K annual
    report for the year ended December 31, 2006. We assume no
    responsibility to update or revise any forward-looking statements to
    reflect events, trends or circumstances after the date they are made.